BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26730880)

  • 1. How you ask is what you get: Framing effects in willingness-to-pay for a QALY.
    Ahlert M; Breyer F; Schwettmann L
    Soc Sci Med; 2016 Feb; 150():40-8. PubMed ID: 26730880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing WTP values of different types of QALY gain elicited from the general public.
    Pennington M; Baker R; Brouwer W; Mason H; Hansen DG; Robinson A; Donaldson C;
    Health Econ; 2015 Mar; 24(3):280-93. PubMed ID: 25625510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
    Nimdet K; Ngorsuraches S
    BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Willingness to pay for a quality-adjusted life-year: the individual perspective.
    Bobinac A; Van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2010 Dec; 13(8):1046-55. PubMed ID: 20825620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Willingness to pay for QALY: perspectives and contexts in Japan.
    Igarashi A; Goto R; Yoneyama-Hirozane M
    J Med Econ; 2019 Oct; 22(10):1041-1046. PubMed ID: 31262236
    [No Abstract]   [Full Text] [Related]  

  • 6. Estimating a constant WTP for a QALY-a mission impossible?
    Sund B; Svensson M
    Eur J Health Econ; 2018 Jul; 19(6):871-880. PubMed ID: 28932914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating a WTP-based value of a QALY: the 'chained' approach.
    Robinson A; Gyrd-Hansen D; Bacon P; Baker R; Pennington M; Donaldson C;
    Soc Sci Med; 2013 Sep; 92():92-104. PubMed ID: 23849283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.
    Mavrodi A; Aletras V
    Value Health Reg Issues; 2020 Sep; 22():36-43. PubMed ID: 32731168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
    Olofsson S; Norrlid H; Persson U
    J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.
    Baker R; Bateman I; Donaldson C; Jones-Lee M; Lancsar E; Loomes G; Mason H; Odejar M; Pinto Prades JL; Robinson A; Ryan M; Shackley P; Smith R; Sugden R; Wildman J;
    Health Technol Assess; 2010 May; 14(27):1-162. PubMed ID: 20525460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
    Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
    PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness to pay for a QALY.
    Gyrd-Hansen D
    Health Econ; 2003 Dec; 12(12):1049-60. PubMed ID: 14673813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of a QALY towards the end of life and its determinants: Experimental evidence.
    Fischer B; Telser H; Zweifel P; von Wyl V; Beck K; Weber A
    Soc Sci Med; 2023 Jun; 326():115909. PubMed ID: 37121067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.
    Rowen D; Brazier J; Mukuria C; Keetharuth A; Risa Hole A; Tsuchiya A; Whyte S; Shackley P
    Med Decis Making; 2016 Feb; 36(2):210-22. PubMed ID: 26670663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
    King JT; Tsevat J; Lave JR; Roberts MS
    Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the design of payment scales on the willingness to pay for health gains.
    Soeteman L; van Exel J; Bobinac A
    Eur J Health Econ; 2017 Jul; 18(6):743-760. PubMed ID: 27623946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year.
    Nielsen JS; Gyrd-Hansen D; Kjaer T
    Health Econ; 2021 May; 30(5):923-931. PubMed ID: 33569834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran.
    Lankarani KB; Ghahramani S; Moradi N; Shahraki HR; Lotfi F; Honarvar B
    Appl Health Econ Health Policy; 2018 Dec; 16(6):837-846. PubMed ID: 30123949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of a QALY: individual willingness to pay for health gains under risk.
    Bobinac A; van Exel J; Rutten FF; Brouwer WB
    Pharmacoeconomics; 2014 Jan; 32(1):75-86. PubMed ID: 24293198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
    Byrne MM; O'malley K; Suarez-Almazor ME
    Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.